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Abstract
Objective : To elaborate on the pathomechanism of 
pregnancy rhinitis and the proper management of rhinitis 
symptoms, particularly nasal obstruction.
Methods: Literature review. 
Methods : Literature review. 
Result: Placental Growth Hormone has a similar effect 
as progesterone in pregnancy, which is peripheral 
vasodilatation and increases extracellular volume. Increased 
estrogen during pregnancy enhances the parasympathetic 
activity, thus increasing vascular permeability and glandular 
activity.Plasma leakage from vascular bed to stroma results 
in edematous turbinates, causing nasal congestion. This 
mucosal swelling is exaggerated with the presence of thick 
and profuse secretion.
Conclusions : Pregnancy rhinitis, manifested as nasal 
congestion, is considered a phenomenon and may become 
a serious condition. Persistent nasal congestion acts as a 
potential risk factor in affecting fetal growth and development 
through gradual hypoxia process. This condition can lead 
to various complications such as maternal hypertension, 
preeclampsia, impaired fetal growth, and low APGAR scores. 
In-depth knowledge of pathomechanism is essential as 
guidance to proper treatment, including conservative and 
medical therapies, which will lead to an optimal outcome for 
both mother and baby.
Keywords : estrogen, nasal congestion, placental growth 
hormone, pregnancy rhinitis.
Abstrak
Tujuan : Untuk memaparkan patomekanisme rinitis 
kehamilan dan tatalaksana yang tepat dalam mengatasi 
gejala rinitisnya, terutama hidung tersumbat.
Metode : Tinjauan pustaka.
Hasil: PGH dan progesterone memiliki efek serupa yaitu 
vasodilatasi perifer dan peningkatan volume ekstraselular. 
Peningkatan estrogen selama kehamilan menstimulus 
aktivitas sistem parasimpatetik, yang mana terjadi 
peningkatan permeabilitas vaskular dan aktivitas kelenjar. 
Kebocoran plasma dari pembuluh darah ke stroma akan 
menyebabkan edema konka yang bermanifestasi sebagai 
kongesti hidung. Kondisi pembengkakan mukosa ini 
diperberat dengan adanya hipersekresi.
Kesimpulan : Rinitis kehamilan, dengan manifestasi 
kongesti hidung, dianggap sebagai suatu fenomena yang 
dapat menjadi fatal. Kongesti hidung persisten merupakan 
faktor risiko terjadinya gangguan tumbuh kembang janin 
melalui proses hipoksia bertahap. Kondisi ini dapat berlanjut 
menimbulkan komplikasi seperti hipertensi maternal, 
preeklamsia, gangguan tumbuh janin, dan skor APGAR 
yang rendah. Memahami patomekanisme sangat utama 
dalam membimbing klinisi memberikan tatalaksana yang 
tepat, termasuk terapi konservatif dan farmaka, yang akan 
memberikan keluaran yang optimal baik bagi ibu dan bayi. 
Kata kunci : estrogen, kongesti hidung, placental growth 
hormone, rinitis kehamilan.
INTRODUCTION
Rhinitis is a common problem during pregnancy, 
affecting up to 30% of pregnant women.1Rhinitis 
during pregnancy might occurs as allergic rhinitis, 
drug-induced rhinitis, rhinosinusitis, anatomical 
variations, and gestational or “pregnancy” 
rhinitis.2 In women with prior history of allergic 
rhinitis, nasal symptoms might improve or worsen 
during their pregnancies.3, 4Demoly1 quoted that 
around 10–30%  pregnant women suffer more 
from their AR symptoms. However, some women 
experience rhinitis symptoms only asepisodes 
in their pregnancies. Thus, pregnancy rhinitis is 
defi ned as nasal congestion present during the 
last six weeks or more of pregnancy, without 
other signs of respiratory tract infection and no 
known allergic cause.Pregnancy rhinitis usually 
disappears within two weeks after delivery1, 3
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Pregnancy rhinitis is reported in one of fi ve 
pregnant women.3 The incidence rate from small 
groupsof pregnant women were respectively 30% 
of 79 women, 18% of 66 women, and 21% of 160 
women. The prevalence of pregnancy rhinitis as 
17.17%, with the description as follows: 0% in the 
fi rst trimester, 9.38% in the second trimester, and 
38.89% in the third trimester.3,4
In a questionnaire study, 22% of 599 pregnant 
women reported having nasal congestion during 
their midwife visits. Rhinitis symptoms occurred 
in their 7th to 36th week of pregnancies and 
disappeared in second to the fourth week after 
delivery. Fourty two percent of 2.264 pregnant 
women had nasal obstruction on the 36th week 
of pregnancies.3
Pregnancy rhinitis is considered as the result 
of hormonal changes and fl uctuation during 
pregnancy, which might manifest as nasal 
congestion as the most bothersome symptom. 
During pregnancy, elevated estrogen and 
progesterone levels are associated with nasal 
mucosal hyperreactivity. These hormones also 
induce mucosal swelling, glandular secretion, 
and dilatation of turbinate capillaries, resulting 
in worsening of symptoms, especially nasal 
obstruction.1, 3, 5
It is believed that placental growth hormone 
(PGH) may stimulate mucosal growth and 
thus induce nasal congestion.Other than that, 
physiological changes during pregnancy also 
attribute to symptoms severity. Increased 
circulating blood volume during pregnancy, up 
to 40% of pre-pregnancy, is related to increased 
nasal airway resistance.5
Due to similar symptoms with other 
infl ammatory diseases of the nose, pregnancy 
rhinitis should be suspected by the exclusion of 
other causes of rhinitis.6, 7 Rhinitis symptoms 
in pregnancy might not be considered as fatal, 
however, worsen symptoms during pregnancy 
may impair maternal daily activities and 
emotional well being. Persistent nasal congestion 
resulting in sleep disturbance during pregnancy 
is related to intrauterine growth retardation and 
lower APGAR scores.3 Proper management of 
pregnancy rhinitis must not raise problems, and 
worth consider the risk-benefi t ratio for mothers 
and infants. 3, 6, 7
The Effects of Pregnancy Hormones to Nasal 
Physiology
Throughout the pregnancy, hormonal changes 
affect the physiologic nasal cycle in many ways. 
Pregnancy-related hormonal changes and 
neuropeptides are causing this alteration to the 
mucosa of the nose.8
Estrogen
Estrogen production dramatically increases 
during pregnancy. Estrogen tends to inhibit 
acetylcholine esterase leading to the production 
of acetylcholine and induces  Parasympathetic 
activity.
This cholinergic activity causesvasodilatation and 
oedema to the nasal mucosa.9, 10 (Figure 1)
In general, estrogen causes nasal turbinates 
to be edematous, leading to nasal obstruction, 
nasal discharge fl owing into the throat (postnasal 
drip). Untreated conditions may cause olfactory 
function disturbance. These rhinitis symptoms 
also occur in women with birth control pills and 
hormonal replacement therapy.12, 13
Other known effects of estrogen are increased 
of vascular permeability, protein synthesis, 
glandular activity and increase the sensitivity 
of vasomotor properties in the autonomic 
nervous system. Increase of protein synthesis 
and hyaluronic acid in the nasal mucosa causes 
the mucus to thicken and disrupt the mucociliary 
clearance of the nasal cycle.9,10In addition, increase 
of blood pooling due to decreasedα-adrenergic 
smooth muscle tonus in the venous sinusoid, 
or oedema caused by plasma leakage from the 
vascular bed to the  stroma.3
Figure 1. Estrogen Effects during Pregnancy11
Excessive mucus production gives a sensation 
to the throat as post nasal drip, thus enhance 
nasal congestion. Studied nasal mucosa biopsies 
from pregnant women and those who consumed 
birth control pills, which he found glandular 
hyperactivities and increased phagocytosis. Nasal 
congestion is the initial side effect of high dose 
estrogen contraceptive pill intake.14 Conducted 
a cohort study of 568 patients and found a 
signifi cant correlation between the incidence 
of asthma and rhinitis during pregnancy. 
Furthermore, β-estradiol and progesterone have 
receptors in nasal mucosa that contribute to the 
nasal congestion pathophysiology in pregnant 
women.12, 13, 15
The signifi cant rise of the plasma volume in 
pregnant womenoccur during the 6 – 8 weeks of 
gestation and reach its peak at week 32. Volume 
may increase to 4700 to 5200 ml (45% increase to 
unpregnant women). This occurrence happened 
due to an increase of estrogen secretion and 
renin angiotensin aldosterone system stimulation, 
which attract water and retent natrium. Water 
retention produces oedema of the mucosa thus 
resulting nasal congestion.11
Estrogen may trigger an immune reaction 
through the α-estrogen receptor on the mast cell. 
This reaction peak during the menstrual period, 
pregnancy, oral contraception consumption and 
hormone replacement therapy. A hypothesisstates 
that estrogen and progesterone act as antigen 
bound to a different protein producing Th2 
cell, which regulates IgE synthesis and other 
antibodies. The antibody linked to mast cells 
as well as appropriate antigens (hormone or 
metabolites) will cause degranulation of the mast 
cell or basophil. Thus releasing histamine, Th2 
cytokines, and leukotrienes.16, 17
Progesterone
There was no difference in blood progesterone 
levelbetween women with and without pregnancy 
rhinitis. Other study showed an increase 
of circulatory blood volume, possibly from 
vasodilatation occurringdue to the increased 
level of progesterone in pregnant women, which 
may induce nasal congestion2. Nasal vascular 
pooling from smooth muscle relaxation related 
to the increase of progesterone. An increase 
of vasoactive intestinal peptide (VIP) release, 
stimulated by progesterone and oxytocin, may 
enhance nasal congestion. Progesterone-related 
fi broblast in the nasal mucosa may also affect the 
extracellular matrix.10
Prolactin
Production of prolactin by pituitary increases 
during pregnancy, which suggests the possibility 
of its role in the pathogenesis of pregnancy 
rhinitis; however, this is contradicted by the 
absence of sinus pathology in patients who have 
prolactinomas. Furthermore, bromocriptine and 
quinagolide reduce prolactin production which 
eventually develops nasal congestion.3
Neuropeptides
A vasoactive intestinal polypeptide (VIP) is 
associated with other forms of rhinitis, and a 
possible mediator for nasal mucosa vasodilation, 
which is responsible for nasal congestion during 
pregnancy. Nasal biopsies of postmenopausal 
women showed an increased immunopositivity 
for estradiol, estradiol receptor, VIP, and 
substance P (SP) after six months of hormone 
replacement therapy. Whereas, there was 
a reduction in neuropeptide Y(NPY). Nasal 
application of hormone replacement therapy 
induced stronger VI P changes than did the 
transdermal application. Mucociliary transport 
time and subjective nasal congestion decreased, 
but anterior rhinomanometry was unchanged. 
The investigators proposed that estrogen action 
in the nasal mucosa is mediated by neuropeptides 
an increase of gland secretion and vasodilatation 
by VIP and SP and a decrease of NPY-induced 
vasoconstriction.3 VIP relaxes the blood vessels 
to the upper airways, trachea, bronchi, and 
pulmonary vessels.
Innervation of the nasal mucosa is mainly 
organized and complex. The autonomic system 
regulates the mucosal vasculature and glandular 
secretion. The efferent nasal refl ex arc consists 
of sympathetic and parasympathetic nerves. 
Parasympathetic nerve stimulates the release 
of acetylcholine, norepinephrine, and VIP. 
Postganglionic parasympathetic nerve innervates 
serous and mucous glands, arteries, veins and 
arteriovenous anastomoses. The distribution of 
VIP-immunoreactive fi bres corresponds to the 
cholinergic distribution system. VIP stimulates 
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serous cell secretion, dilates nasal vessels, and 
may also regulate mucociliary clearance in the 
nose.18
The mechanism of hyperactivity of the nose 
remains unknown. The proposed hypothesis 
is increased permeability and increased the 
sensitivity of sensory nerve endings and imbalance 
of autonomic nerve regulation caused by changes 
of the nasal mucosa neuroreceptors.18Substance 
P is produced by the afferent sensory neurons 
of the trigeminal nerve within the nasal mucosa. 
Neurotransmitter promotes vasodilatation, 
increase blood vessels permeability, and 
hypersecretion of submucosal glands, leading 
to all sorts of nasal symptoms. The exact role of 
this neuropeptide in pregnancy rhinitis remains 
unclear.19
Small-diameter of the unmyelinated sensory 
fi bres which areextensively branched, densely 
innervate the walls of submucosal vessels and 
glandular acini to form the neurosecretory 
varicosities within the vascular and glandular 
area. Neuronal wave evoked by histamine 
immediately extends to the peripheral sensory 
neurons, and the central, brain, as well. Hence, 
various neuropeptides are released from the 
nerve endings into the spaces near submucosal 
vessels and gland to elicit its rapid reactions.19
Placental Growth Hormone
growth hormone (PGH) was signifi cantly high 
during pregnancy. A signifi cantly higher level 
of PGH in women with pregnancy rhinitis group 
on all occasions throughout the pregnancy. 
Presumably, PGH stimulates nasal mucosa similar 
to progesterone, thus inducing pregnancy rhinitis. 
PGH has a similar effect as progesterone in 
pregnancy, which is peripheral vasodilatation and 
increases extracellular volume.20 The mechanism 
is still unknown; further study is warranted.3, 20
Risk Factors
According to a questionnaire study done, the 
incidence of pregnancy rhinitis is signifi cantly 
higher among smoking women than non-smoking 
women (odds ratio: 1,7; CI 95% 1,1-1,5)2,3. Thus, 
smoking is considered an irritant agent that most 
probably stimulates nasal congestion. In vitro test 
to 10 airborne allergensin 165 pregnant women, 
in which 83 women had pregnancy rhinitis14. 
Overall sensitization was not increased in women 
with pregnancy rhinitis, yet sensitization to 
house dust mites frequently occurred in this 
group.Therefore, subjects with a high level of 
IgE to house dust mites are considered prone 
to develop pregnancy rhinitis. However, to 
differentiate pregnancy rhinitis to allergic rhinitis 
in pregnancyis still a challenge.2, 3, 14
DIAGNOSIS
The diagnosis of pregnancy rhinitis is made by 
history taking, consisting thorough information 
regarding symptoms and physical examination 
to eliminate other cause of other nasal disorders. 
This shall exclude allergic rhinitis, vasomotor 
rhinitis, septal deviation, polyposis, rhinosinusitis 
and many more. It is diffi cult to differentiate 
allergic and nonallergic rhinitis. The common 
triggering factor of nonallergic rhinitis may be 
weather or temperature changes, food, perfume, 
strong odour and smoke. Additional symptoms 
may include allergic conjunctivitis (itching, watery, 
redness and swelling of the eye).21
A comprehensive head and neck 
examination starting with a simple rhinoscopy 
or nasoendoscopic examination to exclude 
other cause of rhinitis (Figure 2). The mucosa 
of the nasal and nasal turbinates may appear 
swollen and covered with serous to seromucoid 
discharge. There are no other specifi c further 
fi ndings (laboratory or other means) to diagnose 
Human Growth Hormone (hGH) is secreted in an 
episodic burst in low levels between peaks. This 
pattern is later replaced by continuous secretion 
of Placental Growth Hormone (PGH) after the 
fi rst trimester of gestation.  That placental 
Figure 2. nasoendoscopic fi nding right inferior turbinate
 in pregnancy rhinitis pre (right) and post (left) 
decongestant.3
pregnancy rhinitis.Pregnancy rhinitis is diagnosed 
based on subjective fi ndings of symptoms and 
physical examination.21
Nasal congestion may also be objectively 
assessed by rhinomanometry, acoustic rhinometry, 
or peak nasal inspiratory fl owmetry (PNIF). 
Those examinations assess nasal congestion by 
measuring nasal resistance, nasal volume, and 
nasal airfl ow.24
DIFFERENTIAL DIAGNOSIS
Pregnancy rhinitis is a subtype of non-allergic 
non-infectious (NANIR).  Allergic rhinitis shows 
similar symptoms to pregnancy rhinitis, but 
the underlying pathology occurred due to 
immunoglobulin E-mediated hypersensitivity. 
A defi nitive diagnosis of allergic rhinitis is 
established by skin prick test or specifi c IgE 
serology results.2, 3, 25
Rhinitis medicamentosa is another differential 
diagnosis but may also become a complication 
of pregnancy rhinitis. Most women do not 
directly disclose a history of prolonged usage of 
intranasaldecongestant. Therefore it is essential 
to obtain this information in the history taking. 
Healthy individuals with rhinitis medicamentosa 
no longer have nasal congestion in 2 days after 
they stop using decongestants. During pregnancy, 
if congestion persists for more than a week or 
so after reducing intranasal decongestant, the 
diagnosis should be pregnancy rhinitis.3
Other differential diagnosis includes upper 
respiratory tract infection and anatomical variation 
(septal deviation and hypertrophic turbinates) 
which disrupt the mucociliary clearance. Infection 
may occur due to a virus which causes direct 
damage to the nasal epithelial barrier and 
indirectly by hyperactivity of nasal mucosa, thus 
disrupts mucociliary clearance. It is important to 
exclude sinusitis by the clinical fi nding of purulent 
discharge in the middle meatus, facial pain, and 
olfactory dysfunction. Sinusitis during pregnancy 
(common in the second trimester) may not improve 
with conservative treatment such as nasal saline 
irrigation. Secondary bacterial infection may also 
occur. Typical organisms found in such conditions 
are Streptococcus pneumonia, Haemophilus 
infl uenza, and Moraxella catarrhalis.26
IMPACT OF PREGNANCY RHINITIS
Impact of pregnancy rhinitis to the fetus is 
indirectly related to sleeping disturbance 
The evaluation of subjective nasal obstruction 
using a Visual Analog Score (VAS) and Nasal 
Obstructive Symptom Evaluation (NOSE) scale 
may assess the quality of daily life (Figure 3 
and Table 1). Both tools are highly specifi c and 
sensitive, validated by previous studies on many 
other nasal pathologies. VAS and NOSE scale are 
patient-centred quantitative diagnostic tools. 
VAS score more than 5 and NOSE scale more 
than equal to 5 in pregnant women presumably 
to be pregnancy rhinitis.22
Over the past month, how much of a problem 
were the following conditions for you? Please 
circle the most correct response.
Discharge Infl ammation Polyps/Oedema 
(DIP) score is a clinician-based examination 
validated by previous researches (Table 2). DIP 
score quantifi esnasoendoscopic fi ndings (more 
than 5 to be considered as pregnancy rhinitis). 
A correlation between VAS, NOSE, and DIP 
scores toward gestation in evaluating pregnancy 
rhinitis.4
Figure 3. Visual Analog Scale (VAS)22
Table 1. Nasal Obstructive Symptom Evaluation Scale23
Table 2. Discharge Infl ammation Polyps/Edema (DIP) 
Scoring System24
Mild
Absent
0
Moderat
1
Severe
2
Moderate Fairly bad Severe
Nose obstruction 
and stuffi ness
Nose obstruction
Trouble breathing 
through my nose
Trouble of sleeping
Unable to get 
enough air through 
my nose during 
exercise or exertion
Discharge
Infl ammation
Polyps/Edema
0
0
0
0
0
1
1
1
1
1
2
2
2
2
2
3
3
3
3
3
4
4
4
4
4
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experienced by pregnant women.Besides nasal 
congestion due to placental hormones, lying 
down in bedtime (supine position) also cause more 
nasal congestion due to the effect of gravitation.
Diffi culty in breathing through the nose increases 
the risk of snoring and mouth breathing during 
sleep. Twenty three percent of 502 postpartum 
women reported having to snore at the last weeks 
of their pregnancies. Snoring gives a higher risk 
of developing hypertension, pre-eclampsia, 
intrauterine growth retardation (IUGR), and low 
APGAR scores. Mouth breathing in pregnancy 
rhinitis affects lung vascular tonus or mother/
and fetus oxygenation. Pregnancy rhinitis might 
induce the presence of obstructive sleep apnea 
(OSA).2,3 Physiologically, inhaled nitric oxide, 
which is highly produced inside the maxillary 
sinuses, decreases lung vascular resistance and 
increases lung oxygenation. Nasal congestion 
might disturb nitric oxide production.
Another study stated that pregnancy rhinitis 
impaired women’s quality of life and might cause 
OSA, which in turn disturb pregnancy outcome25. 
Quality of life impairment was most signifi cant at 
the third trimester than the second trimester. In 
addition, there is a signifi cant difference in the 
quality of life between women with and without 
pregnancy rhinitis. Prolonged nasal congestion 
may lead to sinusitis development. Furthermore, 
it may cause cognitive and concentration 
impairment, fatigue, and headache. Pregnancy 
rhinitis is also associated with increased anxiety. 
Mouth breathing, on the other hand, causes dry 
mouth and decreases saliva secretion, leading to 
dental caries due to loss of salivary protection 
effect.
Quality of life in pregnancy rhinitis has not been 
fully evaluated, yet in severe cases, women showed 
diffi culty in achieving optimum respiratory needs 
during the delivery process. Nasal congestion 
acts as a potential risk in hampering fetal growth 
and development by gradual hypoxia.27
MANAGEMENT
Conservative treatment
In the conservative approach, it is essential 
to elaboratetreatment options and goals to 
women with pregnancy rhinitis, which is to 
alleviate symptoms rather than cure the disease. 
Doctors must ensure pregnant women that nasal 
congestion is a common occurrence during 
pregnancy. Such information should be given at 
the fi rst antenatal care visit, along with several 
treatment options to choose.2, 3
Physical Exercise
Physical exercise has been known to have a 
decongestant effect on the nasal mucosa. Head 
elevationat 300– 450 when laying down reduce 
the likelihood of vena cava syndrome and 
snoring. Another mechanical mean is using dilator 
fornostrils. This device dilates the narrowest 
part of the upper airways that is valve area of 
the nose. External type dilator may improve 
nocturnal nasal congestion related to breathing 
in pregnant women, while internal type dilator 
may reduce snoring in men as effective as a nasal 
decongestant. The adverse effect from dilator 
usage would be local irritation of the skin due to 
pressure.28
Nasal Saline Irrigation  
Nasal saline irrigation is effective in improving 
symptoms, by repairing mucociliary clearance, 
reducing mucosal oedema, reducing infl ammatory 
mediators, and cleaning mucus or triggering 
agents. Nasal irrigation is performed using isotonic 
saline solution 30–500 ml (average 200 – 250 ml), 
pH range is 6.2-8.4. Higher volume irrigates a 
wider area in the nasal cavity. Hypertonic solution 
(3% sodium chloride solution) is effective for 
irrigating thick mucus. Depending on device and 
volume, nasal irrigation on average is performed 
in 1 minute with compression pressure ≥120 
mbar to reach areas of the nasal cavity.29
Pharmacology Treatment
A pharmacological agent is an option when 
conservative therapy fails to reduce symptoms of 
pregnancy rhinitis.
Decongestant
Decongestant is a vasoconstrictor agent 
effective to reduce nasal obstruction. Most 
systemic decongestant (phenylephedrine, 
pseudoephedrine, and phenylpropanolamine) is 
classifi ed as category C by the United State Food 
and Drug Administration (US FDA). One study 
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found 206 cases of gastroschisis due to systemic 
decongestant during pregnancy, although 
there has been no study in the effectiveness of 
systemic decongestant for pregnancy rhinitis.3In 
unpregnant women, a decongestant may cause 
systemic side effects such as high blood pressure, 
palpitation, decrease appetite, tremor and sleep 
disturbance.9
Topical decongestants (oxymetazoline and 
phenylephrine) work rapidly to relieve nasal 
congestion. Pregnant women tend to overuse 
nasal decongestant in the long term because 
pregnancy rhinitis is a continuous condition. This 
will lead to unresolved rhinitis medicamentosa 
postdelivery. A topical decongestant will 
occupy α-adrenergic receptors more. Hence 
the autoregulation system will cause rebound 
mucosal oedema and worsen congestion.10, 11 
Benzalkonium chloride, acommon preservative 
in topical decongestantalso aggravate nasal 
congestion. Usage of topical decongestant once 
daily at night for more than four weeks may 
develop into rhinitis medicamentosa.27Therefore 
the recommended dose is a short term use of 
maximum 5-10 days at a lower dosage, unilateral 
and alternating nostril administrationin the 
evening.3, 28
Glucocorticoids
The intranasal steroidgives a very responsive 
therapeutic effect on managing all forms of rhinitis 
(allergicrhinitis, medicamentosa, NANIR and 
sinusitis). Intranasal steroid lowers the need for a 
systemic steroid, and it has an insignifi cant effect 
on pregnancy rhinitis. A RCT study by Ellegard 
et al2showed insignifi cant effects of fl uticasone 
propionate nasal spray given eight weeks to 
pregnancy rhinitis, observedfrom symptoms or 
acoustic rhinometry data. That study also found 
no impact on cortisol level or fetal growth shown 
in the ultrasound. All currently available intranasal 
steroids have extremely low bioavailability,hence 
hardly give systemic side effects. Regardless, US 
FDA classifi es mometasone furoate, fl uticasone 
furoate, fl uticasone propionate, and triamcinolone 
acetonide as category C. According to the Swedish 
Medical Birth Registry, there is no increment 
of congenital malformation incidencein rhinitis 
patients using budesonide inhalation in the early 
gestation. Hence it is classifi ed as category B.2, 3, 
28
Long term and repeated systemic 
corticosteroid usage should be avoided due to 
its adrenal suppression and other systemic side 
effects. A short-term of systemic steroid, less 
than two weeks, may give temporary relief. High 
dose corticosteroid intake gives many risks in 
the fi rst trimester, for example, fetal blindness, 
lung oedema, uterine contraction inhibition, and 
fl uid overload.28 Thus, systemic corticosteroids 
generally should be avoided during pregnancy, 
except in serious threatening condition with 
benefi t/risk ratio concerns.
Antibiotic
Antibiotic is not indicated in pregnancy rhinitis, 
although that would not be the case when 
bacterial sinusitis occurred. Intensive high dose of 
antibiotic is warranted, Beta-lactam dose should 
be increased by 50% because ofrenal clearance 
increase during pregnancy and to reach minimum 
inhibition concentration. Category B antibiotics, 
other than Beta-lactams, include penicillin, 
cephalosporin, aztreonam (monobactam).
Imipenem is classifi ed as category C.3.
Antihistamine
Antihistamine is indicated if histamine-related 
symptoms are suspected, particularly effective 
for relieving sneezing and nasal itching.3,5 
Antihistamine has been used for a long time 
and known to have no adverse effect on 
the fetus. However, classic or 1st generation 
antihistamines (i.e. chlorpheniramine, triprolidine, 
diphenhydramine, cyproheptadine, promethazine, 
ketotifen) show to have side effects due to 
their action. Such side effects are drowsiness, 
dry mouth, and increase appetite.12 Classic 
antihistamines are associated with oral clefts. 
Second and new generation antihistamines (i.e. 
loratadine, cetirizine, fexofenadine, desloratadine, 
levocetirizine) are more preferred due to lack 
of such side effects and no cardiac effects.This 
group of antihistamine is also clinically proven 
to have anti-infl ammatory effects, aside from a 
known H1-histamine receptor blocker. Cetirizine 
and Loratadine are classifi ed as category B.
Other Methods of Management
Nasal Continous Positive Airway Pressure (CPAP) 
is indicated in pregnancy rhinitis with severe 
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obstructive sleep apnea (OSA). In unpregnant 
patient, nasal CPAP is highly effective as shown 
by the improvement in polysomnography 
results. Pressure adjustment must be made in 
pregnant women. A study shows that nasal CPAP 
signifi cantly reduces the nocturnal blood pressure 
in pre-eclamptic women without OSA.3
Surgery
Surgery will only be in consideration in cases with 
worst prognosis due to failure of conservative, 
pharmacological therapy, and other noninvasive 
measures, such as CPAP. It should be thoroughly 
considered that pregnancy rhinitis is a self-limiting 
disease in a certain period.3For refractory nasal 
obstruction due to hypertrophic turbinate, less 
invasive surgical measures include electrocautery, 
cryotherapy, laser or radiofrequency may be 
applied to reduce inferior turbinate volume.
CONCLUSION
Researchers describe pregnancy rhinitis as nasal 
congestion that occurred in6 weeks ormore of 
the last fi nal trimester of pregnancy, without a 
sign of respiratory infection and known allergy, 
which may resolve completely in 2–4 weeks 
postpartum. The most bothersome symptom is 
nasal obstruction, and other symptom includes 
watery rhinorrhea. Its pathomechanism remains 
unclear, although it is believed that estrogen, 
human chorionic gonadotropin hormone (HCG), 
human placental lactogen (HPL), and placental 
growth hormone (PGH) play roles. Risk factors 
include smoking and sensitization.
There is no drug of choice to manage 
pregnancy rhinitis. Women with pregnancy 
rhinitis should receive proper education 
regarding their conditions. Although most 
pregnancy rhinitis spontaneously resolvedafter 
giving birth, symptoms may signifi cantly 
decrease quality of life, and medical attention 
is needed. Management includes conservative 
and pharmacology treatment, which aimed to 
relieve nasal congestion and other symptoms. 
Nonetheless, pregnancy is a specifi c condition 
that needs specifi c consideration. The fi nal goal 
is to have an optimal outcome for both mother 
and baby.
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